Reduction-sensitive mixed micelles for selective intracellular drug delivery to tumor cells and reversal of multidrug resistance

Du, Xiao; Yin, Shaoping; Zhou, Fang; Du, Xu; Xu, Jianan; Gu, Xiaochen; Wang, Guangji; Li, Juan

doi:10.1016/j.ijpharm.2018.08.019

Cited by 26 publications

(15 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, the micelles showed higher tumor accumulation and better tumor inhibition in vivo than the uncleavable controls. Conjugating HA with other polymers through disulfide bond, such as poly (lactide) (PLA) 99 , pyrenyl 100 , 6-mercaptopurine 101 , vitamin E succinate 102 , and curcumin 103 , were all utilized for reduction sensitive drug delivery.…”

Section: Ha In Tumor-targeting Drug Deliverymentioning

confidence: 99%

Development and application of hyaluronic acid in tumor targeting drug delivery

Luo

Dai

Gao

2019

Acta Pharmaceutica Sinica B

261

123

View full text Add to dashboard Cite

Hyaluronic acid (HA) is a natural polysaccharide that has gained much attention due to its biocompatibility, enzyme degradation capacity and active tumor targeting capacity. Its receptor, CD44, is overexpressed in many kinds of cancers and is associated with tumor progress, infiltration and metastasis. Therefore, many researchers have developed various HA-based drug delivery systems for CD44-mediated tumor targeting. In this review, we systemically overview the basic theory of HA, its receptor and hyaluronidase, then we categorize the studies in HA-based drug delivery systems according to the functions of HA, including tumor-targeting materials, enzyme-sensitive biodegradable modality, pH-sensitive component, reduction-sensitive component, and the gel backbone. Finally, the perspective is discussed.

show abstract

Section: Ha In Tumor-targeting Drug Deliverymentioning

confidence: 99%

Development and application of hyaluronic acid in tumor targeting drug delivery

Luo

Dai

Gao

2019

Acta Pharmaceutica Sinica B

261

123

View full text Add to dashboard Cite

show abstract

“…In contrast, taxol and MSNs seemed to be less effective in inhibiting the tumor growth, which could be attributed to the limited intratumoral H 2 O 2 concentration that lead to a relatively low therapy efficacy. Body weight was another evaluation parameter to check for adverse effects of the testing preparations 22. As shown in Figure 9E, mice in the saline or nanoparticles groups all showed no weight loss for the duration of the study, while taxol treatment showed a significant reduction, demonstrating a satisfactory safety profile for MSNs-GOx/PLL/HA nanoparticles.…”

Section: Resultsmentioning

confidence: 95%

“…The coumarin (C6) labeled nanoparticles were prepared in a same way with PTX-loaded nanoparticles. Drug loading capability (DL) was calculated according to previous report 22…”

Section: Methodsmentioning

confidence: 99%

<p>Glucose-responsive mesoporous silica nanoparticles to generation of hydrogen peroxide for synergistic cancer starvation and chemistry therapy</p>

Du¹,

Tian²,

Ma³

et al. 2019

IJN

Self Cite

View full text Add to dashboard Cite

Background: The combination of novel starving therapy with chemotherapy is one of the most promising strategies to achieve an effective antitumor activity. Methods: Herein, we developed a multifunctional mesoporous silica nanoparticle (MSNs-GOx/PLL/HA) coated with poly (L-lysine) (PLL) and hyaluronic acid (HA) for co-delivery of glucose oxidase (GOx) and anticancer drug paclitaxel (PTX) for cancer treatment for the first time. Compared to single chemotherapy, introduction of GOx would not only selectively trigger the consumption of intracellular glucose, leading to the interruption of energy supply, but also elevat the endogenous H 2 O 2 level, inducing stronger therapeutic effects. Results: The novel drug delivery system possessed desirable particle diameter of 40 nm and exhibited a pH-sensitive drug release behavior. An in vitro cellular uptake study indicated that MSNs-GOx/PLL/HA nanoparticles effectively enhanced the cellular uptake of drug in an apparently CD44 receptor-dependent manner, and delivered more cargo into cytoplasm via endolysosomal escape effect in presence of PLL. The nanoplatform has also demonstrated amplified synergistic therapeutic effects for remarkable tumor inhibition in a xenograft animal tumor model. Conclusion: Consequently, the developed synergistic starving-like/chemotherapy may provide a potential platform for next generation cancer therapy.

show abstract

“…In brief, cells were washed twice with PBS containing 0.5% BSA and 2 mmol/L EDTA; resuspended in hypotonic citrate buffer (2.5 mmol/L sodium chloride, 1.25 mmol/L sodium citrate, and 3.5 mmol/L dextrose) containing 20 mg/mL PI solution, APC-conjugated CD41a antibody, 10 U/mL RNase A, and 0.05% TritonX 100; and incubated for 20 min in the dark. The MMP was measured using the MMP assay kit with JC-1 in accordance with the manufacturer's recommendations [30]. Cells were seeded into 24-well plates at a density of 5 Â 10 5 cells/well and treated with the abivertinib, Z-VAD-FMK, or staurosporine for 48 h. Cells were then incubated with 5 mg/mL JC-1 at 37 °C for 20 min.…”

Section: Mk Adhesion Spreading and Morphologymentioning

confidence: 99%

Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis

Huang

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Abivertinib, a third-generation tyrosine kinase inhibitor, is originally designed to target epidermal growth factor receptor (EGFR)-activating mutations. Previous studies have shown that abivertinib has promising antitumor activity and a well-tolerated safety profile in patients with non-small-cell lung cancer. However, abivertinib also exhibited high inhibitory activity against Bruton's tyrosine kinase and Janus kinase 3. Given that these kinases play some roles in the progression of megakaryopoiesis, we speculate that abivertinib can affect megakaryocyte (MK) differentiation and platelet biogenesis. We treated cord blood CD34 + hematopoietic stem cells, Meg-01 cells, and C57BL/6 mice with abivertinib and observed megakaryopoiesis to determine the biological effect of abivertinib on MK differentiation and platelet biogenesis. Our in vitro results showed that abivertinib impaired the CFU-MK formation, proliferation of CD34 + HSC-derived MK progenitor cells, and differentiation and functions of MKs and inhibited Meg-01-derived MK differentiation. These results suggested that megakaryopoiesis was inhibited by abivertinib. We also demonstrated in vivo that abivertinib decreased the number of MKs in bone marrow and platelet counts in mice, which suggested that thrombopoiesis was also inhibited. Thus, these preclinical data collectively suggested that abivertinib could inhibit MK differentiation and platelet biogenesis and might be an agent for thrombocythemia.

show abstract

Reduction-sensitive mixed micelles for selective intracellular drug delivery to tumor cells and reversal of multidrug resistance

Cited by 26 publications

References 63 publications

Development and application of hyaluronic acid in tumor targeting drug delivery

Development and application of hyaluronic acid in tumor targeting drug delivery

<p>Glucose-responsive mesoporous silica nanoparticles to generation of hydrogen peroxide for synergistic cancer starvation and chemistry therapy</p>

Abivertinib inhibits megakaryocyte differentiation and platelet biogenesis

Contact Info

Product

Resources

About